Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea

NCT07280221 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07280221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07280221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 10, 2025
Completion date
October 31, 2027
Enrollment
500 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

obesity